Fundação Bahiana de Infectologia
Quick facts
Phase 3 pipeline
- Dolutegravir plus lamivudine in a FDC · Infectious Disease
Dolutegravir inhibits HIV integrase to prevent viral DNA integration into the host genome, while lamivudine inhibits reverse transcriptase to block HIV replication.
Phase 2 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Fundação Bahiana de Infectologia portfolio CI brief
- Fundação Bahiana de Infectologia pipeline updates RSS
Frequently asked questions about Fundação Bahiana de Infectologia
What is Fundação Bahiana de Infectologia's pipeline?
Fundação Bahiana de Infectologia has 1 drugs in Phase 3, 1 in Phase 2, 0 in Phase 1. Late-stage candidates include Dolutegravir plus lamivudine in a FDC.
Related
- Sector hub: All tracked pharma companies